Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Rucaparib
100%
BRCA2
100%
Gene Alteration
100%
BRCA1 Gene
100%
BRCA2 Gene
100%
Prostate-specific Antigen Response
37%
Breast Cancer Susceptibility Gene 1 (BRCA1)
25%
Response Rate
25%
Measurable Disease
25%
Radiology Review
25%
Prostate Cancer
12%
Twice Daily
12%
Solid Tumors
12%
Antitumor Activity
12%
Cancer Clinical Trials
12%
Germ Cells
12%
Anemia
12%
Androgens
12%
Safety Profile
12%
PARP Inhibitor (PARPi)
12%
Cancer-related
12%
Taxane-based Chemotherapy
12%
Objective Response Rate
12%
Tumor Subtype
12%
Two-line
12%
Response Evaluation Criteria in Solid Tumors (RECIST)
12%
Treatment-related Adverse Events
12%
Medicine and Dentistry
Castration Resistant Prostate Cancer
100%
Rucaparib
100%
Gene Mutation
100%
BRCA1
100%
BRCA2
100%
Prostate Specific Antigen
33%
Antigen Response
33%
Radiology
22%
Diseases
22%
Prostate Cancer
11%
Clinical Trial
11%
Solid Malignant Neoplasm
11%
Somatics
11%
Adverse Event
11%
PARP Inhibitor
11%
Anemia
11%
Antineoplastic Activity
11%
Androgen
11%
Germ Cell
11%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
100%
Rucaparib
100%
Prostate Specific Antigen
60%
Diseases
40%
Clinical Trial
20%
Chemotherapy
20%
Antitumor Activity
20%
Prostate Cancer
20%
Solid Malignant Neoplasm
20%
Adverse Event
20%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
20%
Anemia
20%
Androgen
20%
Taxane
20%